Загрузка...
A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer
BACKGROUND: Advanced renal cell cancer (RCC) continues to have a poor overall prognosis despite new FDA-approved therapies. Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics. Mi...
Сохранить в:
Главные авторы: | , , , , , , , |
---|---|
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
2008
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2704464/ https://ncbi.nlm.nih.gov/pubmed/18501078 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|